13237
clinical study

Cost-Effectiveness Analysis of AI-Driven Pulmonary Embolism Response Team Activation in Mechanical Thrombectomy

Materials & Methods

This retrospective study analyzed data from an academic tertiary referral hospital in a large metropolitan area. Patients diagnosed with acute pulmonary embolism (PE) who underwent mechanical thrombectomy between 2020 and 2024 were identified. Two cohorts were compared: those managed before AI implementation and those managed after the adoption of an AI-based Pulmonary Embolism Response Team (PERT) alert system (Aidoc) in early 2022. The primary metrics assessed included intensive care unit (ICU) length of stay (LoS), hospital LoS, and cost savings. Cost analysis was based on an estimated daily ICU cost of $3,500.

Results

A total of 13 patients met the inclusion criteria. The average ICU stay was reduced from 13 days in the pre-AI group to 10 days in the post-AI group, reflecting a 23% reduction. Similarly, the overall hospital stay was reduced from 17 days to 14 days, representing an 18% decrease. In terms of cost, ICU expenses per patient dropped from $45,500 in the pre-AI period to $35,000 in the post-AI period, leading to an average cost savings of $10,500 per patient. Extrapolating these savings to an estimated annual volume of 48 thrombectomies, the total projected yearly cost savings amounted to approximately $504,000. Given that the estimated total cost per thrombectomy patient is around $70,000, AI implementation led to a 15% reduction in overall per-patient expenses.

Conclusions

AI-driven PERT activation for mechanical thrombectomy in acute PE patients was associated with reduced ICU and hospital stays by an average of three days each, leading to cost savings of approximately $10,500 per patient. These findings support the integration of AI-based solutions into acute PE management protocols to improve efficiency, reduce healthcare costs, and enhance patient outcomes.

Explore the Latest AI Insights, Trends and Research

Daniel Spector

<p>Daniel Spector is an AI Transformation Consultant at Aidoc. His focus is enabling clinicians and hospital administrators to provide better, more efficient care through the power of AI augmentation for enterprise imaging.</p>

Amalia Schreier

<p>Amalia Schreier serves as the Senior Vice President of Regulatory Affairs and Legal at Aidoc, guiding our company and product’s regulatory strategies and ensuring alignment with AI-focused medical device compliance requirements. Since her tenure began, she has streamlined our FDA clearance processes, emphasizing a meticulous approach that underscores our commitment to product and clinical quality.</p> <p>With a solid foundation from her legal background and leadership role in AI startup regulatory departments, Schreier brings invaluable insights and expertise to our regulatory framework. Prior to her tech world experience, she worked as a human-rights lawyer and legal policy scholar, with a BA and LLM in law from the Hebrew University of Jerusalem.</p>

Deepak Srikant

<p>Deepak Srikant is a global marketing executive with over 20 years of experience, specializing in the commercialization of medical devices and digital health solutions. He has a proven track record in driving growth, having led successful go-to-market strategies, product launches and market expansions across the U.S. and EMEA.</p> <p>Srikant’s expertise extends to upstream and downstream marketing, professional education and sales enablement. His leadership at companies such as Silk Road Medical (acquired by Boston Scientific) and Aptus Endosystems (acquired by Medtronic) has consistently resulted in revenue growth, enhanced customer retention and successful product adoption.</p> <p>Srikant holds an MBA from the Yale School of Management and a bachelor’s degree in mechanical engineering from Rensselaer Polytechnic Institute. Currently, he leads product marketing for Aidoc’s cardiovascular service line.</p>